McKesson Reports Strong Q4 & FY26 Results, Exceeds Targets, Issues Positive FY27 Guidance, and Authorizes $7.7B Share Repurchase
Summary
McKesson reported strong Q4 and full-year FY26 results, exceeding growth targets, issued positive FY27 guidance, and authorized a significant $7.7 billion share repurchase program.
Key Events
-
Strong Q4 and Full Year FY26 Performance
Consolidated revenues increased 6% to $96.3 billion for Q4 and 12% to $403.4 billion for the full year. Adjusted Earnings per Diluted Share rose 16% to $11.69 in Q4 and 18% to $39.11 for the full year, exceeding previously communicated long-range growth targets.
-
Positive Fiscal 2027 Adjusted EPS Guidance
The company established its fiscal 2027 Adjusted Earnings per Diluted Share guidance range at $43.80 to $44.60, indicating a forecasted growth of 12% to 14% compared to the prior year.
-
Substantial Share Repurchase Authorization
McKesson's Board of Directors approved a $5.0 billion increase to the share repurchase program, bringing the total authorization to $7.7 billion as of April 2026. The company also entered into a $2.25 billion accelerated share repurchase program during the fourth quarter.
-
Strategic Portfolio Optimization Progress
The company continued its strategic initiatives, including the planned separation of its Medical-Surgical Solutions segment with Apollo Global acquiring a 13% minority ownership interest, and the completion of its exit from European operations.
Analysis
McKesson Corporation delivered robust fourth-quarter and full-year fiscal 2026 results, surpassing its long-range growth targets with significant increases in revenue and adjusted EPS. The company also provided an optimistic adjusted EPS guidance for fiscal year 2027, projecting 12% to 14% growth. This strong financial performance is complemented by a substantial capital return strategy, including a new $5.0 billion increase to its share repurchase authorization, bringing the total to $7.7 billion. Investors should view this filing as a strong signal of operational excellence, continued growth, and a commitment to shareholder value, reinforcing the company's strategic direction and financial health.
At the time of this filing, MCK was trading at $752.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $92.4B. The 52-week trading range was $637.00 to $999.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.